

**Comparison of 24-month completers versus patients who discontinued/were lost to follow-up between Months 6 and 24 (N=501)**

	<b>Completed</b>	<b>Did not complete</b>	<b>p-value</b>
n (%)	277 (55.3)	244 (44.7)	
Gender, n (%)			0.2050
Female	251 (90.6)	195 (87.1)	
Male	26 (9.4)	29 (12.9)	
Median age (range) at belimumab initiation	40.0 (18.0–72.0)	41.0 (19.0–79.0)	0.5340
Race/Ethnicity, n (%)			0.1194
Caucasian	146 (52.7)	119 (53.1)	
African-American	69 (24.9)	54 (24.1)	
Hispanic	43 (15.5)	45 (20.1)	
Other	19 (6.9)	6 (2.7)	
Time since diagnosis (from baseline), n (%)			0.1614
0–5 years	162 (58.5)	117 (52.2)	
>5 years	115 (41.5)	107 (47.8)	
Disease severity at baseline, n (%)			0.6482
Mild/moderate	218 (78.7)	180 (80.4)	
Severe	59 (21.3)	44 (19.6)	
Anti-dsDNA positive and low C3/C4, n (%)			0.0140
Yes	153 (55.2)	99 (44.2)	
No	124 (44.8)	125 (55.8)	
SELENA-SLEDAI >10			0.9718 (excluding N/A group)
Yes	60 (21.7)	26 (11.6)	
No	25 (9.0)	11 (4.9)	
N/A	192 (69.3)	187 (83.5)	
Steroid ≥7.5 mg/day			0.5401
Yes	195 (70.4)	152 (67.9)	
No	82 (29.6)	72 (32.1)	

N/A, not available

Supplementary file 6. Clinical outcome measures for the 24 month completer population (where data were available); A. Disease severity according to physician assessment (N=277); B. SELENA-SLEDAI; C. Steroid use among patients prescribed oral steroids at baseline.

